In the Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin was administered to CKD patients with an estimated glomerular filtration rate (eGFR) of 25 to 75 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio of 200 to 5000 mg/gCr [8]. The gene discussed is ALB; the disease is chronic kidney disease.